HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 28, 19081-19091, July 14, 2006

This Article Full Text Full Text (PDF) All Versions of this Article: 281/28/19081    most recent M600116200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jung, D. Articles by Meyer, U. A. Search for Related Content PubMed PubMed Citation Articles by Jung, D. Articles by Meyer, U. A. Social Bookmarking                      What's this?

Pregnane X Receptor Is a Target of Farnesoid X Receptor^*

Diana Jung¹, David J. Mangelsdorf, and Urs A. Meyer

From the Division of Pharmacology and Neurobiology, Biozentrum, University of Basel, CH 4056 Basel, Switzerland and Department of Pharmacology, Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9050

The pregnane X receptor (PXR) is an essential component of the body's detoxification system. PXR is activated by a broad spectrum of xenobiotics and endobiotics, including bile acids and their precursors. Bile acids in high concentrations are toxic; therefore, their synthesis is tightly regulated by the farnesoid X receptor, and their catabolism involves several enzymes regulated by PXR. Here we demonstrate that the expression of PXR is regulated by farnesoid X receptor. Feeding mice with cholic acid or the synthetic farnesoid X receptor (FXR) agonist GW4064 resulted in a robust PXR induction. This effect was abolished in FXR knock-out mice. Long time bile acid treatment resulted in an increase of PXR target genes in wild type mice. A region containing four FXR binding sites (IR1) was identified in the mouse Pxr gene. This region was able to trigger an 8-fold induction after GW4064 treatment in transactivation studies. Deletion or mutation of single IR1 sites caused a weakened response. The importance of each individual IR1 element was assessed by cloning a triple or a single copy and was tested in transactivation studies. Two elements were able to trigger a strong response, one a moderate response, and one no response to GW4064 treatment. Mobility shift assays demonstrated that the two stronger responding elements were able to bind FXR protein. This result was confirmed by chromatin immunoprecipitation. These results strongly suggest that PXR is regulated by FXR. Bile acids activate FXR, which blocks synthesis of bile acids and also leads to the transcriptional activation of PXR, promoting breakdown of bile acids. The combination of the two mechanisms leads to an efficient protection of the liver against bile acid induced toxicity.

Received for publication, January 5, 2006 , and in revised form, May 5, 2006.

^* This study was supported by the Swiss National Science Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Division Pharmacology/Nurobiology Biozentrum, University Basel, Klingelbergstrasse 50/70, CH 4056 Basel, Switzerland. Tel.: 41-612672241; Fax: 41-612672208; E-mail: Diana.jung{at}unibas.ch.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. M. Tompkins, T. L. Sit, and A. D. Wallace Unique Transcription Start Sites and Distinct Promoter Regions Differentiate the Pregnane X Receptor (PXR) Isoforms PXR 1 and PXR 2 Drug Metab. Dispos., May 1, 2008; 36(5): 923 - 929. [Abstract] [Full Text] [PDF]

				M. L. Hubbert, Y. Zhang, F. Y. Lee, and P. A. Edwards Regulation of Hepatic Insig-2 by the Farnesoid X Receptor Mol. Endocrinol., June 1, 2007; 21(6): 1359 - 1369. [Abstract] [Full Text] [PDF]